FY2030 Earnings Forecast for VYGR Issued By HC Wainwright

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Voyager Therapeutics in a note issued to investors on Wednesday, February 4th. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.83) per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

A number of other research analysts have also commented on the company. Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Voyager Therapeutics Trading Down 5.3%

Shares of NASDAQ VYGR opened at $3.54 on Friday. The firm has a market cap of $196.82 million, a P/E ratio of -1.64 and a beta of 1.30. The business’s 50 day moving average is $4.05 and its 200-day moving average is $4.07. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.73.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.06. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. The firm had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can bought a new stake in Voyager Therapeutics during the second quarter worth about $36,000. Wexford Capital LP acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $42,000. ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics during the 4th quarter worth approximately $44,000. R Squared Ltd acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $48,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $50,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.